Guangzhou Hongyun Medical Scientific and Technological

Hongyun Pharma is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the development of next-generation small molecule precision medicines for oncology. The company leverages a structure-based drug discovery platform to design highly selective inhibitors targeting well-validated but challenging pathways such as EGFR, SHP2, and KRAS. Its lead program, H002, is a fourth-generation EGFR inhibitor designed to overcome resistance mutations in non-small cell lung cancer. Hongyun Pharma aims to address significant unmet medical needs in the global cancer market through innovative chemistry and deep biological insights.